pentetic acid has been researched along with gefitinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bailey, KE; Cai, Z; Chen, Z; Costantini, DL; Reilly, RM; Scollard, DA; Vallis, KA | 1 |
1 review(s) available for pentetic acid and gefitinib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for pentetic acid and gefitinib
| Article | Year |
|---|---|
Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
Topics: Antineoplastic Agents; Cell Compartmentation; Cell Line, Tumor; Cell Nucleus; Electrons; Epidermal Growth Factor; ErbB Receptors; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gefitinib; Humans; Indium Radioisotopes; Pentetic Acid; Phosphorylation; Protein Transport; Quinazolines; Radiopharmaceuticals; Signal Transduction | 2007 |